SCHEMBL22096896

SCHEMBL22096896

CONC(=O)Nc1c(F)cncc1C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
P2RY1 P47900 1/20 0.32
STIM1 Q13586 1/20 0.32
ORAI1 Q96D31 1/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 1/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ATR Q13535 1/20 0.31
IMPDH2 P12268 1/20 0.30
LPAR1 Q92633 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096836 0.85 PDE4D (0.37) PDE4APDE4BPDE4CPDE4DSTIM1
SCHEMBL22096869 0.83 PDE4D (0.42) PDE4APDE4BPDE4CPDE4D
SCHEMBL19780240 0.81 PDE4D (0.36) PDE4APDE4BPDE4CPDE4DSTIM1
SCHEMBL21883563 0.78 NAMPT (0.36) PDE4APDE4BPDE4CPDE4DP2RY1
SCHEMBL22096841 0.78 ALDH1A1 (0.43) PDE4APDE4BPDE4CPDE4DP2RY1
SCHEMBL22096827 0.78 KMT2A (0.37) P2RY1KDM4EALDH1A1GAALPAR1
SCHEMBL19780243 0.77 LPAR1 (0.37) PDE4APDE4BPDE4CPDE4DP2RY1
SCHEMBL22096823 0.73 GPR35 (0.37) ALDH1A1CYP1A2CYP2C19
SCHEMBL19780239 0.72 PDE4A (0.32) PDE4APDE4BPDE4CPDE4DIMPDH2
SCHEMBL19780244 0.71 TAS1R3 (0.32) PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10875839-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-12-29 US disclosed
US-20200190053-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2020-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190053-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 PDE4A 92/4885PDE4B 113/4885PDE4C 164/4885
US-10875839-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 PDE4A 92/4885PDE4B 113/4885PDE4C 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.